• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

70
2
2
2
1

COUNTRY

2
1

PRICE

10
15
18
75

PUBLISHED

0
2
4
75

PRODUCT TYPE

75

Leukemia

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

PRODUCT TITLE
Leukemia Drug Pipeline Update 2014 Leukemia Drug Pipeline Update 2014 - Product Thumbnail Image

Leukemia Drug Pipeline Update 2014

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 292 companies plus partners developing 417 leukemia drugs in 632 developmental...

July 2014
FROM
Leukemia Drug Pathway Analyzer 2014 Leukemia Drug Pathway Analyzer 2014 - Product Thumbnail Image

Leukemia Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 379 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways...

July 2014
FROM

Leukemia Treatment Drugs Markets in China

China's demand for Leukemia Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic...

June 2014
FROM
Analytical Tool - Leukemia Analytical Tool - Leukemia - Product Thumbnail Image

Analytical Tool - Leukemia

"Analytical Tool - Leukemia" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of...

March 2014
Triple Analysis: Colorectal Cancer, Leukemia and Melanoma Triple Analysis: Colorectal Cancer, Leukemia and Melanoma - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Leukemia and Melanoma

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Antibodies Triple Analysis: Leukemia, Melanoma and Antibodies - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Prostate Cancer Triple Analysis: Leukemia, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Angiogenesis Triple Analysis: Leukemia, Melanoma and Angiogenesis - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Leukemia, Lung Cancer and Melanoma Triple Analysis: Leukemia, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Leukemia, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Protein Kinase Inhibitors Triple Analysis: Leukemia, Melanoma and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts...

June 2013
FROM
Triple Analysis: Breast Cancer, Leukemia and Melanoma Triple Analysis: Breast Cancer, Leukemia and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Leukemia and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Apoptosis Triple Analysis: Leukemia, Melanoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Leukemia, Apoptosis and Peptides Triple Analysis: Leukemia, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Leukemia, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share

GBI Research, the leading business intelligence provider, has released its latest research “Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share”...

November 2012
FROM
Triple Analysis: Leukemia, Pancreatic Cancer and Antibodies Triple Analysis: Leukemia, Pancreatic Cancer and Antibodies - Product Thumbnail Image

Triple Analysis: Leukemia, Pancreatic Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

November 2012
FROM
Triple Analysis: Leukemia, Angiogenesis and Antibodies Triple Analysis: Leukemia, Angiogenesis and Antibodies - Product Thumbnail Image

Triple Analysis: Leukemia, Angiogenesis and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies)....

November 2012
FROM
Triple Analysis: Colorectal Cancer, Leukemia and Antibodies Triple Analysis: Colorectal Cancer, Leukemia and Antibodies - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Leukemia and Antibodies

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

November 2012
FROM
Triple Analysis: Leukemia, Apoptosis and Antibodies Triple Analysis: Leukemia, Apoptosis and Antibodies - Product Thumbnail Image

Triple Analysis: Leukemia, Apoptosis and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies)....

November 2012
FROM
Triple Analysis: Breast Cancer, Leukemia and Antibodies Triple Analysis: Breast Cancer, Leukemia and Antibodies - Product Thumbnail Image

Triple Analysis: Breast Cancer, Leukemia and Antibodies

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

November 2012
FROM
Loading Indicator

Our Clients

Our clients' logos